LSCs can be characterized by a distinct immune phenotype within the CD34+CD38- AML fraction regularly expressing such important surface proteins, such as CD123, TIM-3, CLL-1, CD70, CD44v6, or GPR56. Here, CLEC12A is linked to acute myeloid leukemia.